Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing antifungal medicines based on its proprietary triterpenoid antifungal platform known as "fungerps." News about SCYNEXIS frequently centers on clinical data, regulatory interactions, collaborations, and its exclusive license agreement with GSK for ibrexafungerp, the active ingredient in the FDA-approved product BREXAFEMME for vulvovaginal candidiasis and reduction in the incidence of recurrent VVC.
On this page, readers can follow company announcements related to the development of next-generation fungerps, including SCY-247, which SCYNEXIS describes as a second-generation triterpenoid antifungal under clinical and preclinical evaluation for invasive fungal infections. Recent updates have highlighted positive Phase 1 single and multiple ascending dose results, preclinical data presented at scientific congresses, and plans for additional studies using both oral and intravenous formulations.
SCYNEXIS news also covers key events in its collaboration with GSK, such as the transfer of the BREXAFEMME New Drug Application, resolution of disagreements regarding the Phase 3 MARIO study in invasive candidiasis, and associated milestone or other payments. Regulatory and listing developments, including Nasdaq minimum bid price notices and extensions to regain compliance, are disclosed through company press releases and SEC filings.
Investors, clinicians, and researchers can use this news feed to review updates on clinical trial progress, antifungal data presentations, license agreement developments, and corporate milestones. Regularly checking this page helps users track how SCYNEXIS advances its fungerp platform, manages its partnership with GSK, and responds to regulatory and market requirements.
SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated an underwritten public offering of common stock and warrants, including pre-funded warrants. The underwriters may purchase up to an additional 15% of the offered shares within 30 days. This offering is subject to market conditions, and no guarantees are made regarding its completion or terms. Guggenheim Securities is the book-running manager. The offering is based on a shelf registration statement filed with the SEC, originally effective in January 2021. SCYNEXIS is known for its lead antifungal drug, ibrexafungerp, aimed at treating drug-resistant infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced the presentation of interim data from its Phase 3 FURI and CARES studies focusing on ibrexafungerp, a novel antifungal agent, at the 32nd ECCMID in Lisbon, Portugal, from April 23-26, 2022. Highlights include an oral presentation on patient outcomes and various poster sessions on treatment efficacy for serious fungal infections including Candida auris. The company emphasizes its commitment to addressing drug-resistant infections and the potential of ibrexafungerp as a broad-spectrum antifungal therapy.
SCYNEXIS has announced that BREXAFEMME (ibrexafungerp tablets) is now accessible to about 55% of commercially insured U.S. patients, covering more than 93 million lives. This first-in-class oral antifungal treatment addresses an unmet need for vaginal yeast infections, particularly in resistant cases. The drug, approved by the FDA in June 2021, demonstrates efficacy against Candida species. The company anticipates ongoing increases in insurance coverage and prescription volumes as they pursue broader access for women.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in three women’s health conferences throughout April 2022, showcasing its commitment to advancing women’s health. The company, known for developing BREXAFEMME (ibrexafungerp), the first oral treatment for vaginal yeast infections approved in over 20 years, aims to discuss innovative treatments. The conferences include the ACOOG Annual Conference (April 3-8), NBNPA Conference (April 29-30), and Ms. Medicine Women’s Health Conference (April 28-30). Each event will address significant advancements in women’s health.
SCYNEXIS reported significant achievements for 2021, with BREXAFEMME generating $1.1 million in net revenues. The fourth quarter alone saw revenues of $0.6 million. The product is now covered by commercial insurance representing 48% of insured lives. The successful CANDLE Phase 3 trial claims statistical superiority over placebo for ibrexafungerp in treating recurrent vulvovaginal candidiasis. SCYNEXIS has projected a cash runway extending into the second quarter of 2023.
SCYNEXIS, Inc. (NASDAQ: SCYX) will announce its fourth quarter and full year 2021 financial results on March 29, 2022. The company, dedicated to developing innovative medicines for difficult-to-treat infections, plans to hold a conference call at 8:30 a.m. EDT to discuss the results. SCYNEXIS's lead product, ibrexafungerp, is a systemic antifungal approved by the FDA on June 1, 2021, and is set for launch in the U.S. as BREXAFEMME. The company is continuing investigations into ibrexafungerp for other significant fungal infections.
Summary not available.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced grants of stock options and Restricted Stock Units (RSUs) to three new employees, totaling 28,000 stock options at an exercise price of $4.18 and 11,500 RSUs. This move aims to attract talent in the biotechnology sector focusing on innovative treatments for drug-resistant fungal infections. The options will vest over a four-year period, while the RSUs will vest over three years. These grants are part of SCYNEXIS’ 2015 Inducement Award Plan, aligned with their mission to develop medicines like ibrexafungerp, aimed at combating serious fungal infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in several medical events throughout March 2022. Key highlights include a live panel discussion on drug development in Women’s Health, led by CEO Marco Taglietti. The company will attend three in-person conferences: ISSWSH from March 3-6 in Dallas, CREOG & APGO Annual Meeting from March 9-12 in Orlando, and AMCP from March 29-April 1 in Chicago. Additionally, SCYNEXIS will participate in a virtual investor panel at Maxim Group’s Annual Growth Conference on March 28.
For more details, visit www.scynexis.com.
SCYNEXIS reported successful results from the Phase 3 CANDLE study for ibrexafungerp, the only oral fungicidal treatment for vaginal yeast infections. The study showed 65.4% of patients treated with ibrexafungerp had clinical success at 24 weeks, surpassing the 53.1% success rate of the placebo group. The company plans to submit a supplemental New Drug Application (sNDA) for BREXAFEMME for preventing recurrent vaginal yeast infections in the first half of 2022, with anticipated FDA approval by year-end. Ibrexafungerp has potential benefits for patients not responding to fluconazole.